Novozymes A/S Company Profile (OTCMKTS:NVZMY)

About Novozymes A/S (OTCMKTS:NVZMY)

Novozymes A/S logoNovozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America. It develops and distributes solutions within the market areas agriculture, bioenergy, food & beverages, household care, leather, pharmaceuticals, forest products, textile and wastewater solutions. Novozymes operates through a range of partnerships with companies, such as Adisseo, Beta Renewables, DONG Energy and Monsanto, and is a parent company of Novozymes Belgium BVBA, Novozymes BioAg Limited, Novozymes Canada Limited, Albumedix A/S and Organobalance GmbH, among others.

Industry, Sector and Symbol:
  • Sector: Basic Materials
  • Industry: N/A
  • Sub-Industry: N/A
  • CUSIP: N/A
  • Web:
  • Market Cap: $11.29649 billion
  • Outstanding Shares: 296,961,000
Average Prices:
  • 50 Day Moving Avg: $44.58
  • 200 Day Moving Avg: $41.09
  • 52 Week Range: $31.57 - $49.25
  • Trailing P/E Ratio: 29.03
  • Foreward P/E Ratio: 26.01
  • P/E Growth: 22.61
Sales & Book Value:
  • Annual Revenue: $2.19 billion
  • Price / Sales: 6.17
  • Book Value: $5.66 per share
  • Price / Book: 8.04
  • Annual Dividend: $0.37
  • Dividend Yield: 0.8%
  • EBIDTA: $769.9 million
  • Net Margins: 21.58%
  • Return on Equity: 27.40%
  • Return on Assets: 16.74%
  • Current Ratio: 1.48%
  • Quick Ratio: 0.92%
  • Average Volume: 23,336 shs.
  • Beta: 1.1

Frequently Asked Questions for Novozymes A/S (OTCMKTS:NVZMY)

What is Novozymes A/S's stock symbol?

Novozymes A/S trades on the OTCMKTS under the ticker symbol "NVZMY."

How were Novozymes A/S's earnings last quarter?

Novozymes A/S (OTCMKTS:NVZMY) issued its earnings results on Thursday, August, 6th. The company reported $0.33 EPS for the quarter, missing analysts' consensus estimates of $0.35 by $0.02. Novozymes A/S had a net margin of 21.58% and a return on equity of 27.40%. View Novozymes A/S's Earnings History.

Where is Novozymes A/S's stock going? Where will Novozymes A/S's stock price be in 2017?

4 analysts have issued 1-year price objectives for Novozymes A/S's shares. Their predictions range from $47.50 to $47.50. On average, they anticipate Novozymes A/S's stock price to reach $47.50 in the next year. View Analyst Ratings for Novozymes A/S.

Who are some of Novozymes A/S's key competitors?

Who are Novozymes A/S's key executives?

Novozymes A/S's management team includes the folowing people:

  • Joergen Buhl Rasmussen, Chairman of the Board
  • Peder Holk Nielsen, President, Chief Executive Officer
  • Agnete Raaschou-Nielsen, Vice Chairman of the Board
  • Benny D. Loft, Executive Vice President, Corporate Functions; Chief Financial Officer
  • Thomas Videbaek, Chief Operating Officer; Executive Vice President, Research, Innovation & Supply
  • Andrew Fordyce, Executive Vice President, Food & Beverages
  • Anders Lund, Executive Vice President, Household Care & Technical
  • Tina Sejersgaard Fanoe, Executive Vice President, Agriculture & Bioenergy
  • Lena Bech Halskov, Director, Employee Representative
  • Lars Hall Green, Director

How do I buy Novozymes A/S stock?

Shares of Novozymes A/S can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novozymes A/S's stock price today?

One share of Novozymes A/S stock can currently be purchased for approximately $45.52.

MarketBeat Community Rating for Novozymes A/S (OTCMKTS NVZMY)
Community Ranking:  1.2 out of 5 ()
Outperform Votes:  21 (Vote Outperform)
Underperform Votes:  69 (Vote Underperform)
Total Votes:  90
MarketBeat's community ratings are surveys of what our community members think about Novozymes A/S and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Novozymes A/S (OTCMKTS:NVZMY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $47.50

Analysts' Ratings History for Novozymes A/S (OTCMKTS:NVZMY)
DateFirmActionRatingPrice TargetDetails
5/10/2017Jefferies Group LLCReiterated RatingHold$47.50View Rating Details
2/10/2017J P Morgan Chase & CoDowngradeOverweight -> NeutralView Rating Details
1/5/2017Sanford C. BernsteinUpgradeMkt Perform -> OutperformView Rating Details
9/27/2016Berenberg BankInitiated CoverageSellView Rating Details
1/20/2016Goldman Sachs Group, Inc. (The)UpgradeSell -> NeutralView Rating Details
8/7/2015Nordea Equity ResearchDowngradeBuy -> HoldView Rating Details
(Data available from 7/21/2015 forward)


Earnings History for Novozymes A/S (OTCMKTS:NVZMY)
Earnings by Quarter for Novozymes A/S (OTCMKTS:NVZMY)
Earnings History by Quarter for Novozymes A/S (OTCMKTS NVZMY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/22/2015$0.36$0.36ViewN/AView Earnings Details
8/6/2015$0.35$0.33ViewN/AView Earnings Details
4/24/2015$0.33$0.33ViewN/AView Earnings Details
1/20/2015$0.23$0.30ViewN/AView Earnings Details
10/27/2014$0.35$0.34ViewN/AView Earnings Details
8/15/2014$0.38$0.34ViewN/AView Earnings Details
5/20/2014$0.33$0.40ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Novozymes A/S (OTCMKTS:NVZMY)
Current Year EPS Consensus Estimate: $1.61 EPS
Next Year EPS Consensus Estimate: $1.75 EPS


Dividend History for Novozymes A/S (OTCMKTS:NVZMY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Novozymes A/S (OTCMKTS:NVZMY)
No insider trades for this company have been tracked by


Headline Trends for Novozymes A/S (OTCMKTS:NVZMY)
Latest Headlines for Novozymes A/S (OTCMKTS:NVZMY)
DateHeadline logoNovozymes A/S - (NVZMY) Stock Rating Reaffirmed by Jefferies Group LLC - May 10 at 2:48 PM logoNovozymes A/S :NVZMY-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017 - April 28 at 7:55 PM logoKMG Chemicals (KMG) Hits New 52-Week High on Solid Prospects - April 3 at 9:40 AM logoAre microbes the next revolution coming to Big Ag? - January 28 at 5:20 AM logo6:53 am Novozymes higher by 2% overseas following FY16 results - January 18 at 9:00 AM logoNovozymes upgraded by JP Morgan - December 9 at 6:53 PM logoConsumer Staples Delivered Top-Notch Performance for VGEAX - April 29 at 9:08 AM logoAn Above-Average Year for FHJUX - March 21 at 12:29 PM logoThe Fidelity Advisor Europe Fund: An Above-Average Year - February 22 at 7:03 PM logoKerry Group Plc - The Biggest Fish In The Highly Fragmented Ingredient Market - Seeking Alpha - January 30 at 1:44 PM logoHow the Fidelity Advisor Europe Fund Allocated Its Portfolio in 2015 - January 25 at 4:11 PM logoNovozymes upgraded by Goldman - January 20 at 8:22 AM logoNovozymes profit up; sees moderate growth in 2016 - MarketWatch - January 19 at 12:34 PM logoNovozymes profit up; sees moderate growth in 2016 - January 19 at 12:34 PM logoA Look at FHJUX’s Portfolio through November 2015 - December 23 at 5:00 PM logoThe Fidelity Advisor Europe Fund Class A (FHJUX): Historical Overview - October 28 at 2:02 PM logoThere is uncertainty around biofuels: Novzymes CEO - October 22 at 2:15 AM logoNovozyme earnings weaker than expected - August 6 at 2:15 AM logoEuropean Stocks Rise on Climb in German Investor Confidence - January 20 at 6:24 AM



Novozymes A/S (NVZMY) Chart for Friday, July, 21, 2017

This page was last updated on 7/21/2017 by Staff